Polycystic Ovary Syndrome is a common endocrine and reproductive disorder characterised by a combination of ovulatory dysfunction, clinical or biochemical androgen excess and characteristic ovarian morphology, with diagnosis requiring exclusion of other conditions that can produce similar findings. The name can be misleading because not every affected person has polycystic-appearing ovaries, and the ovarian appearance is not the defining feature by itself.
Diagnostic criteria differ somewhat between systems, with the widely used Rotterdam framework generally requiring two of three features: evidence of hyperandrogenism, evidence of irregular or absent ovulation, and polycystic ovarian morphology, after alternative causes have been excluded. Polycystic Ovary Syndrome can affect fertility, menstrual patterns, skin and hair, metabolic health and psychological wellbeing. It is a heterogeneous syndrome, meaning that two people with the same diagnosis can have very different combinations and degrees of symptoms.
The underlying biology of Polycystic Ovary Syndrome involves interactions among ovarian function, hypothalamic-pituitary signalling, insulin metabolism, androgen production and genetic and environmental influences. Many affected people have increased androgen production from the ovaries, and some also have increased adrenal androgen activity. Insulin resistance is common but is not universal and is not required for diagnosis.
Compensatory higher insulin concentrations can stimulate ovarian androgen production and reduce hepatic production of sex-hormone-binding globulin, increasing the proportion of circulating testosterone that is biologically available. Follicular development can become disrupted, producing numerous small follicles that fail to progress normally to a dominant follicle and Ovulation. This combination of endocrine and follicular abnormalities helps explain irregular cycles, fertility difficulties and androgen-related symptoms without reducing the syndrome to a single hormonal abnormality.
Menstrual and reproductive manifestations commonly arise from irregular or absent Ovulation. People may experience infrequent periods, unpredictable bleeding or prolonged intervals between menstrual periods. Because ovulation is inconsistent, conception can be more difficult, although Polycystic Ovary Syndrome does not mean permanent infertility. Some individuals ovulate spontaneously and conceive without fertility treatment, while others require interventions to restore regular ovulation.
The condition is also associated with biochemical or clinical hyperandrogenism, which can manifest as increased facial or body hair, acne or scalp hair thinning. The severity of these features does not necessarily correspond to the severity of reproductive or metabolic abnormalities. A person can have significant androgen excess without dramatic visible symptoms, while another may experience substantial hair growth or acne with relatively modest laboratory abnormalities.
Ovarian morphology can be assessed with ultrasound, although diagnostic interpretation depends on the imaging technology, transducer characteristics, ovarian volume and number or distribution of follicles. The term “polycystic” refers to the appearance of multiple small follicles rather than numerous pathological cysts in the conventional sense. Many healthy people can have ovaries containing multiple follicles, particularly at certain reproductive ages, so ovarian appearance alone should not be equated with Polycystic Ovary Syndrome.
Diagnostic criteria have evolved as ultrasound technology has improved and as clinicians have recognised the limited specificity of morphology alone. Laboratory assessment of androgen levels can support diagnosis, but results require careful interpretation because reference ranges vary, assays differ in quality and hormone concentrations fluctuate. Alternative explanations for androgen excess or menstrual disturbance must be considered before assigning the diagnosis.
Polycystic Ovary Syndrome has important metabolic associations. Insulin resistance, impaired glucose regulation, dyslipidaemia, elevated blood pressure and increased long-term risk of type 2 diabetes occur more frequently in affected populations, although risk varies considerably between individuals. Higher body weight is common in many populations but is not required for diagnosis, and lean individuals can also have substantial metabolic dysfunction. Conversely, not every person with higher body weight has Polycystic Ovary Syndrome.
This distinction is important because the syndrome is a diagnosis based on reproductive and endocrine features, not body size. Metabolic assessment may include evaluation of glucose regulation, blood pressure and lipid profile according to clinical guidance and individual risk. Lifestyle interventions that improve physical activity, nutrition and metabolic health can benefit many patients, regardless of whether substantial weight loss occurs.
Management depends on the individual's main concerns and can include treatment of menstrual irregularity, androgen-related symptoms, metabolic risk and infertility. Combined hormonal contraception can regulate bleeding and reduce androgenic symptoms in suitable patients, while other hormonal or dermatological treatments can target particular manifestations. Metformin may be used in selected patients, particularly where metabolic dysfunction or impaired glucose regulation is relevant, although it is not a universal treatment for every feature.
For people seeking pregnancy who do not ovulate regularly, medicines designed to induce ovulation can be effective, with treatment selected according to current evidence and individual circumstances. Hair-removal methods and targeted dermatological treatment can address unwanted hair growth or acne. Management is therefore multidimensional rather than centred on one medicine or one laboratory value.
Polycystic Ovary Syndrome has implications across the reproductive lifespan. Symptoms often emerge around puberty or early reproductive years, but diagnosis during adolescence requires caution because irregular cycles and acne can be normal features of puberty. Long-term management may include monitoring for metabolic disease and addressing endometrial consequences of prolonged periods without adequate progesterone exposure.
Irregular ovulation can allow the endometrium to remain stimulated by oestrogen without the regular progesterone-driven shedding associated with ovulatory cycles, increasing the risk of endometrial hyperplasia over time. Psychological symptoms, including anxiety, depression and concerns about body image or appearance, can also be important. These issues should be assessed on their own merits rather than assumed to be inevitable consequences of the endocrine disorder.
The history of Polycystic Ovary Syndrome reflects changing ideas about its biological definition. Early descriptions focused on enlarged ovaries containing multiple cyst-like structures and reproductive symptoms, while modern understanding recognises a heterogeneous endocrine syndrome with reproductive and metabolic components. The term remains useful but can create misconceptions because the ovaries are not always polycystic in appearance and the syndrome is not fundamentally a disease of ovarian cysts.
Different diagnostic criteria can classify somewhat different populations, which explains why prevalence estimates vary. Research continues into genetics, insulin signalling, androgen biology, developmental influences and the relationship between reproductive and metabolic features. No single cause or universal mechanism explains every case, so clinical care increasingly focuses on the individual's phenotype and long-term risk rather than treating all patients as biologically identical.
